Entity

Time filter

Source Type

Charlottesville, VA, United States

Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 463.48K | Year: 2015

DESCRIPTION provided by applicant Liver cell based systems are widely used to study drug metabolism toxicity and liver disease However the poor correlation between in vitro data and clinical outcomes is very real and attributed in part to the missing physiological context of the hepatic microenvironment sinusoidal flow and transport three dimensional architecture and heterotypic cell cell interactions HemoShear LLC is a biotechnology research company that utilizes patented methodologies US to restore in vivo biology to animal and human primary cells in co culture in vitro Recently under the SBIR mechanism HemoShear has commercialized in vitro rat and human primary hepatocyte systems that combine physiological principles of hemodynamics and transport to restore and maintain in vivo like differentiated hepatocyte phenotype and function Primary hepatocytes in this system respond to drugs and risk factors at concentrations that approximate in vivo and clinical response levels a major advantage for our commercial partners see Letters of Support However in spite of the rapid commercial uptake of this single cell type system primary hepatocytes only this platform could fail to capture drug toxicities requiring the involvement of multiple liver cell types e g non parenchymal cells NPCs resulting in preclinical false negatives that manifest toxicity in the clinic The purpose of this Fast Track SBIR is to develop a human physiological hepatocyte NPC multi cellular liver system and validate drugs that are known to cause drug induced liver injury through an NPC mediated process for which there are currently no such preclinical human based systems PUBLIC HEALTH RELEVANCE Liver cell based systems are widely used to study drug metabolism toxicity and liver disease However the poor correlation between in vitro data and clinical outcomes is very real and attributed in part to the missing physiological context of the hepatic microenvironment sinusoidal flow and transport three dimensional architecture and heterotypic cell cell interactions HemoShear LLC is a biotechnology research company that utilizes patented methodologies US to restore in vivo biology to animal and human primary cells in co culture in vitro HemoShear has commercialized in vitro rat and human primary hepatocyte systems that combine physiological principles of hemodynamics and transport to restore and maintain in vivo like differentiated hepatocyte phenotype and function The purpose of this Fast Track SBIR is to develop a human physiological hepatocyte NPC multi cellular liver system and validate drugs that are known to cause drug induced liver injury through an NPC mediated process for which there are currently no such preclinical human based systems


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.69M | Year: 2015

DESCRIPTION provided by applicant Human inducible pluripotent stem cells iPSCs proliferate readily and can be terminally differentiated into hepatocytes which potentially makes them an attractive cost effective resource compared to primary human hepatocytes Moreover the ability to standardize a platform to a single human donor or donor s who may include known genetic drug metabolism polymorphism s can eliminate or greatly reduce donor donor variability associated with primary hepatocytes Unfortunately it has been clearly demonstrated that differentiated iPSC derived hepatocytes iHCs though similar to primary hepatocytes in many ways retain certain andquot fetalandquot like aspects This includes increased expression of fetal like proteins e g fetal protein and decreased activity of specific cytochrome p enzymes e g the CYP A family which is responsible for metabolizing over of drugs Thus the pharmaceutical industry and regulatory agencies view the use of iHCs as promising but currently limited Attempts to andquot matureandquot these cells in novel hepatocyte platforms have not proven successful HemoShear is a biotechnology research company that utilizes patented methodologies to restore in vivo responsiveness to human primary cells in vitro We commercialized a human primary hepatocyte platform that combines physiological principles of controlled hemodynamics and transport to restore and maintain mature in vivo like differentiated phenotype morphology and metabolic function Hepatocytes in this platform respond to drugs and hormones at in vivo concentrations The purpose of this Fast Track SBIR is to develop an iHC platform using the HemoShear technology to mature iHC differentiated function and drug responses at physiological levels providing the framework for commercializing a much needed platform for drug safety and efficacy assessment PUBLIC HEALTH RELEVANCE Human inducible pluripotent stem cells iPSCs proliferate readily and can be terminally differentiated into hepatocytes which potentially makes them an attractive cost effective resource compared to primary human hepatocytes for drug discovery and development Unfortunately it has been clearly demonstrated that differentiated iPSC derived hepatocytes iHCs though similar to primary hepatocytes in many ways retain certain andquot fetalandquot like aspects Thus the pharmaceutical industry and regulatory agencies view the use of iHCs as promising but currently limited HemoShear is a biotechnology research company that utilizes patented methodologies to restore in vivo responsiveness to human primary cells in vitro The purpose of this Fast Track SBIR is to develop an iHC platform using the HemoShear technology to mature iHC differentiated function and drug responses at physiological levels providing the framework for commercializing a much needed platform for drug safety and efficacy assessment


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.20M | Year: 2015

DESCRIPTION provided by applicant Drug induced vascular injury DIVI is a common phenomenon in pre clinical animal studies and is typically characterized by hemorrhage vascular endothelial and smooth muscle cell necrosis medial blood cell infiltration and inflammation Mechanisms underlying DIVI are not well understood for several reasons A DIVI result in a preclinical GLP animal study can interrupt or stop the progression of a promising drug to the clinic In addition GLP safety studies in non human primates required to de risk early DIVI findings in lower species are costly HemoShear LLC is a biotechnology research company that utilizes patented methodologies US to restore in vivo biology to animal and human primary cells in co culture in vitro The HemoShear vascular system exposes primary endothelial cells to vascular region specific hemodynamics in co culture with primary smooth muscle cells In this system vascular cells are rescued from a non physiological andquot stateandquot as indicated by restoration of region specific in vivo morphology and function Importantly cells in the HemoShear system demonstrate an efficacious or toxic response to drugs at concentrations that approximate in vivo animal or human exposure levels which are often to orders of magnitude different from standard D static cell culture systems HemoShearandapos s preliminary data with known DIVI compounds show that our science can predict unforeseen DIVI in vitro and prior to pre clinical GLP studies In HemoShear received the Tibbetts SBIR Award from the Small Business Administration for commercialization of innovation The purpose of this SBIR is to further validate the HemoShear DIVI platform for routine commercial application and prospective decision making in pre clinical drug discovery and development PUBLIC HEALTH RELEVANCE Drug induced vascular injury DIVI is a common phenomenon in pre clinical animal studies and is typically characterized by hemorrhage vascular endothelial and smooth muscle cell necrosis medial blood cell infiltration and inflammation Mechanisms underlying DIVI are not well understood for several reasons A DIVI result in a preclinical GLP animal study can interrupt or stop the progression of a promising drug to the clinic HemoShear LLC is a biotechnology research company that utilizes patented methodologies US to restore in vivo biology to animal and human primary cells in co culture in vitro HemoShearandapos s preliminary data with known DIVI compounds show that our science can predict unforeseen DIVI in vitro and prior to pre clinical GLP studies In HemoShear received the Tibbetts SBIR Award from the Small Business Administration for commercialization of innovation The purpose of this SBIR is to further validate the HemoShear DIVI platform for routine commercial application and prospective decision making in pre clinical drug discovery and development


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 249.01K | Year: 2014

DESCRIPTION (provided by applicant): R43 SBIR: Development of an iPSC-derived human vascular system for drug development. ABSTRACT Human inducible pluripotent stem cells (iPSCs) can be differentiated into vascular endothelial (iEC) and smooth muscle (iSMC)cells and hold immense potential for developing drugs in genetically defined subpopulations and for patients with vascular rare diseases, such as Marfan's syndrome, from which iPSCs can be acquired. However, it has not been clearly demonstrated that iECsand iSMCs are phenotypically similar to differentiated human primary adult vascular cells, including disease risk factor and drug responsiveness. This cannot be understated as recent studies with iPSC-derived hepatocytes have shown that these cells provide limited utility to the FDA and pharmaceutical industry for drug discovery as they retain many fetal -like characteristics, failin to express primary hepatocyte levels of many cytochrome p450 enzymes, including the CYP3A family, which is responsible


Patent
HemoShear | Date: 2014-10-21

Methods for mimicking a tumor microenvironment in vitro are provided. The methods comprise indirectly applying a shear stress upon at least one tumor cell type plated on a surface within a cell culture container. Methods for mimicking tumor metastasis and methods for testing drugs or compounds in such systems are also provided.

Discover hidden collaborations